Immunosuppressants - Uganda

Uganda

The Immunosuppressants market in Uganda is projected to reach a revenue of US$9.01m in 2024.
It is expected to show an annual growth rate of 15.17% (CAGR 2024-2029), resulting in a market volume of US$18.26m by 2029.
In global comparison, United States is anticipated to generate the highest revenue, reaching US$35,470.00m in 2024.
In Uganda, the demand for immunosuppressants is rising due to an increasing prevalence of autoimmune diseases and organ transplant surgeries.

Key regions: Australia, Germany, United Kingdom, United States, France

Market

Region

Region comparison

Currency

Analyst Opinion

The Immunosuppressants market in Uganda has been seeing a steady growth in recent years.

Customer preferences: The customers in Uganda prefer generic immunosuppressants due to their affordability compared to branded ones. They also prefer immunosuppressants that have fewer side effects and can be taken orally.

Trends in the market: The market has seen an increase in the number of patients with autoimmune diseases and organ transplant recipients, which has led to an increase in the demand for immunosuppressants. The government has also been increasing its spending on healthcare, which has led to an increase in the availability of immunosuppressants in the market. Additionally, there has been a rise in medical tourism, where patients from neighboring countries come to Uganda for medical treatment, including organ transplants, which has further boosted the demand for immunosuppressants.

Local special circumstances: Uganda has a high prevalence of communicable diseases such as malaria, HIV/AIDS, and tuberculosis, which can lead to the development of autoimmune diseases. Additionally, the country has a shortage of medical personnel, which has led to a high demand for immunosuppressants as a form of treatment for autoimmune diseases.

Underlying macroeconomic factors: The Ugandan economy has been growing steadily, with an increase in the country's GDP. The government has been investing in infrastructure development, which has led to an increase in foreign investment. This has led to an increase in the availability of immunosuppressants in the market. However, the country still faces challenges such as a high poverty rate and a lack of access to healthcare in rural areas, which can limit the growth of the immunosuppressants market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.